Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an Expansion Cohort at the Recommended Phase 2 Dose

NCT01485744 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01485744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01485744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an Expansion Cohort at the Recommended Phase 2 Dose
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2011
Completion date
November 30, 2019
Enrollment
39 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer